. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Curr Opin Biotechnol. 2019 Mar 5;60:146–152. doi: 10.1016/j.copbio.2019.01.013

Table 1.

Studies Utilizing Pathologic BBB Disruption	Neuropathology	Particle Type	Therapeutic Payload
*Madhankumar AB et al.* [**28]	U87 GBM	IL-13r targeting Liposomes	Doxorubicin
Sattiraju A et al. [29]	U87 GBM	α_vβ₃-targeting Liposomes	²²⁵Ac
Sun Z et al. [26]	C6 Glioma	IL-4r targeting Polylactide NC	Doxorubicin
Wang S et al. [27]	U87 GBM	IL-6r targeting Hispolyplex	pING4
Monaco I et al. [30]	U87 GBM	Pdgfrβ targeting Polymeric NC	mTOR inhibitor
Fukuta T et al. [37]	MCAO Stroke	Pegylated Liposome	Fasudil
Partoazar A et al. [38]	MCAO Stroke	Pegylated Liposome	Cyclosporine A
Mann AP et al. [41]	TBI	Peptide targeting Pegylated Au and Si NC	siRNA
Sarkar S et al. [47]	AD	Polylactide NC	L-ascorbic acid
Pahuja R et al. [48]	6-OHDA, PD	PLGA NC	Dopamine

NC=nanocarrier His=histidine, PLGA=poly(D,L-lactide-co-glycolide), ING4=inhibitor of growth 4, GBM=glioblastoma multiforme, MCAO=middle cerebral artery occlusion, TBI=traumatic brain injury, 6-OHDA=6-hydroxydopamine, PD=parkinson’s disease